Influence of cardiac resynchronization therapy on indices of inflammation, the prothrombotic state and tissue remodeling in systolic heart failure: A pilot study

Thrombosis Research

Volumn 128, Issue 4, 2011, Pages 391-394

  Marín, Francisco ^a,b   Roldán, Vanessa ^c   Martínez, Juan Gabriel ^a   Hernández Madrid, Antonio ^d   Hernández Romero, Diana ^b   Ortego, Mónica ^e   Ibáñez, Alicia ^a   Marín Marín, Irene ^d   Navarro, Xavier ^e   Lip, Gregory Y H ^f   Moro, Concepción ^d  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO REINA SOFÍA   (Spain)

^c UNIVERSITY OF MURCIA   (Spain)

^d HOSPITAL RAMÓN Y CAJAL   (Spain)

^e Medtronic Iberica SA   (Spain)

^f UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

C reactive protein; carboxy terminal telopeptide of collagen type I; Cardiac Resynchronization Therapy; CITP; CRP; CRT; F1 + 2; Matrix metalloproteinase 1; Matrix metalloproteinase 2; MMP 1; MMP 2; Prothrombin fragment 1 + 2; TIMP 1; Tissue inhibitor of matrix metalloproteinase 1

Indexed keywords

BIOLOGICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; PROTHROMBIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; CARDIAC RESYNCHRONIZATION THERAPY; CLINICAL ARTICLE; DOWN REGULATION; ENZYME ACTIVITY; FEMALE; FUNCTIONAL STATUS; HEART VENTRICLE REMODELING; HOSPITALIZATION; HUMAN; INFLAMMATION; LETTER; MALE; MORTALITY; PRIORITY JOURNAL; QUALITY OF LIFE; SIGNAL TRANSDUCTION; SYSTOLIC DYSFUNCTION; SYSTOLIC HEART FAILURE; THROMBOSIS;

AGED; BIOLOGICAL MARKERS; BLOOD COAGULATION; C-REACTIVE PROTEIN; CARDIAC RESYNCHRONIZATION THERAPY; CASE-CONTROL STUDIES; COLLAGEN TYPE I; FEMALE; HEART FAILURE, SYSTOLIC; HUMANS; INFLAMMATION MEDIATORS; MALE; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; PEPTIDE FRAGMENTS; PEPTIDES; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS; PROTHROMBIN; SPAIN; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TREATMENT OUTCOME; VENTRICULAR REMODELING;

EID: 80054890035     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2011.05.022     Document Type: Letter

References (31)

1. A. Auricchio, J.C. Spinelli, S.I. Trautman, and M. Kloss Effect of resynchronization therapy on ventricular remodeling J Card Fail 8 2002 S549 S555
2. W.T. Abraham, W.G. Fisher, A.L. Smith, D.B. Delurgio, A.R. Leon, and E. Loh Cardiac resynchronization in chronic heart failure N Eng J Med 346 2002 1845 1853 (Pubitemid 34603028)
3. D.J. Bradley, E.A. Bradley, K.L. Baughman, R.D. Berger, H. Calkins, and S.N. Goodman Cardiac resynchronization and death from progressive heart failure: a meta-analysis of randomized controlled trials JAMA 289 2003 730 740 (Pubitemid 37430368)
4. F.G. Spinale Matrix Metalloproteinases. Regulation and dysregulation in the failing heart Circ Res 90 2002 520 530 (Pubitemid 34640901)
5. F.G. Spinale, M.L. Coker, C.V. Thomas, J.D. Walker, R. Mukherjee, and L. Hebbar Timedependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure Relation to ventricular and myocyte function Circ Res 82 1998 482 495 (Pubitemid 28117330)
6. C.V. Thomas, M.L. Coker, J.L. Zellner, J.R. Handy, A.J. Crumbley, and F.G. Spinale Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy Circulation 97 1998 1708 1715 (Pubitemid 28211420)
7. F.G. Spinale, M.L. Coker, L.J. Heung, B.R. Bond, H.R. Gunasinghe, and T. Etoh A matrix metalloproteinase induction/ activation system exists in the human left ventricular myocardium and is upregulated in heart failure Circulation 102 2000 1944 1949
8. D.L. Mann Inflammatory mediators and the failing heart. Past, present, and foreseeable future Circ Res 91 2002 988 998 (Pubitemid 35416635)
9. M.H. Hessel, G.B. Bleeker, J.J. Bax, M.M. Henneman, B. den Adel, and M. Klok Reverse ventricular remodeling after cardiac resynchronization therapy is associated with a reduction in serum tenascin-C and plasma matrix metalloproteinase-9 levels Eur J Heart Fail 9 2007 1058 1063 (Pubitemid 47451814)
10. I. García-Bolao, A. Macias, B. López, A. Gonzalez, J.J. Gavira, and P. Azcarate A biomarker of myocardial fibrosis predicts long-term response to cardiac resynchronization therapy J Am Coll Cardiol 47 2006 2335 2337 (Pubitemid 43795078)
11. R.S. Vasan, L.S. Sullivan, R. Roubenoff, C.A. Dinarello, T. Harris, and E.J. Benjamin Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction The Framingham Heart Study Circulation 107 2003 1486 1491 (Pubitemid 36378485)
12. M. Rauchhaus, W. Doehner, D. Francis, C. Davos, M. Kemp, and C. Liebenthal Plasma cytokine parameters and mortality in patients with chronic heart failure Circulation 102 2000 3060 3067
13. R. Kell, A. Haunstetter, T.J. Dengler, C. Zugck, W. Kübler, and M. Haass Do cytokines enable risk stratification to be improved in NYHA functional class III patients? Comparison with other potential predictors of prognosis Eur Heart J 23 2002 70 78 (Pubitemid 35215121)
14. I. Kardys, A.M. Knetsch, G.S. Bleumink, J.W. Deckers, A. Hofman, and B.H. Stricker C-reactive protein and risk of heart failure The Rotterdam Study Am Heart J 152 2006 514 520 (Pubitemid 44233424)
15. V. Roldán, F. Marín, J. Pineda, V.E. Climent, J.G. Martínez, and P. Marco Thrombogenic and endothelial damage markers in patients with ischemic systolic impairment Rev Esp Cardiol 54 2001 1155 1160 (Pubitemid 33048971)
16. G.Y.H. Lip, and C.R. Gibbs Does heart failure confer a hypercoagulable state? Virchow's triad revisited J Am Coll Cardiol 33 1999 1424 1426
17. R. Marcucci, A.M. Gori, F. Giannotti, M. Baldi, V. Verdiani, and S. Del Pace Makers of hypercoagulability and inflammation predict mortality in patients with heart failure J Thromb Haemost 4 2006 1017 1022
18. S.A. Hunt, D.W. Baker, M.H. Chin, M.P. Cinquegrani, A.M. Feldman, and G.S. Francis American College of Cardiology/AmericanHeart Association. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure) J Am Coll Cardiol 38 2001 2101 2113 (Pubitemid 33116591)
19. J.G. Cleland, J.C. Daubert, E. Erdmann, N. Freemantle, D. Gras, and L. Kappenberger Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CArdiac REsynchronization-Heart Failure (CARE-HF) trial extension phase] Eur Heart J 27 2006 1928 1932 (Pubitemid 44297365)
20. M.B. Kronborg, P.T. Mortensen, R.E. Kirkfeldt, and J.C. Nielsen Very long term follow-up of cardiac resynchronization therapy: Clinical outcome and predictors of mortality Eur J Heart Fail 10 2008 796 801
21. A. Auricchio, and W.T. Abraham Cardiac resynchronization therapy: current state of the art Cost versus benefits Circulation 109 2004 300 307 (Pubitemid 38133893)
22. F.M. Fruhwald, A. Fahrleitner-Pammer, R. Berger, F. Leyva, N. Freemantle, and E. Erdmann Early and sustained effects of cardiac resynchronization therapy on N-terminal pro-B-type natriuretic peptide in patients with moderate to severe heart failure and cardiac dyssynchrony Eur Heart J 28 2007 1592 1597 (Pubitemid 47227112)
23. Ravassa S, García-Bolao I, Zudaire A, Macías A, Gavria JJ, Beaumont J, Arias T, Huerta A and Díez J. Cardiac resynchronization therapy-induced left ventricular reverse remodelling is associated with reduced plasma annexin A5. Cardiovasc Research. doi:10.1093/cvr/cvq183.
24. G. Boriani, F. Regoli, D. Saporito, C. Martignani, T. Toselli, and M. Biffi Neurohormones and inflammatory mediators in patients with heart failure undergoing cardiac resynchronization therapy: time courses and prediction of response Peptides 27 2006 1776 1786 (Pubitemid 43880376)
25. R.P. Tracy Thrombin, inflammation, and cardiovascular disease Chest 124 2003 49 57
26. C. Patterson, G.A. Stouffer, N. Madamanchi, and M.S. Runge New tricks for old dogs: nonthrombotic effects of thrombin in vessel wall biology Circ Res 88 2001 987 997 (Pubitemid 34137110)
27. V. Roldán, F. Marín, J.R. Gimeno, F. Ruiz Espejo, J. González, and E. Feliu Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy Am Heart J 156 2008 85 91 (Pubitemid 351862294)
28. C. Laviades, N. Varó, J. Fernández, G. Mayor, M.J. Gil, and I. Monreal Abnormalities of the extracellular degradation of collagen type I in essential hypertension Circulation 98 1998 535 540 (Pubitemid 28371251)
29. A. Jordán, V. Roldán, M. García, J.V. Monmeneu, F. García de Burgos, and G.Y.H. Lip Matrix metalloproteinase-1 and its inhibitor, TIMP-1, in systolic heart failure: relation to functional data and prognosis J Intern Med 262 2007 385 392 (Pubitemid 47246973)
30. M.M. Lindsay, P. Maxwell, and F.G. Dunn A marker of left ventricular diastolic dysfunction and fibrosis in hypertension Hypertension 40 2002 136 141 (Pubitemid 34840088)
31. I. García-Bolao, B. López, A. Macías, J.J. Gavira, P. Azcárate, and J. Díez Impact of collagen type I turnover on the long-term response to cardiac resynchronization therapy Eur Heart J 29 2008 898 906 (Pubitemid 351499498)